Collectively, these data suggested that exogenous S1P stimulated the development of regorafenib resistance, indicating that SphK2 could promote regorafenib resistance in HCC by catalyzing the generation of S1P. The gene discussed is SPHK2; the disease is hepatocellular carcinoma.